查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1547545

全球血管性血友病治療市場研究報告 - 2024 年至 2032 年產業分析、規模、佔有率、成長、趨勢與預測

Global Von Willebrand Disease Treatment Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032
出版日期: | 出版商: Value Market Research | 英文 222 Pages | 商品交期: 最快1-2個工作天內

價格

全球血管性血友病治療市場需求預計將從2023年的6.0192億美元達到2032年近10.6541億美元的市場規模，2024-2032年研究期間複合年成長率為6.55%。

馮維勒布蘭氏症 (VWD) 是由一種稱為馮維勒布蘭德因子 (VWF) 的蛋白質缺乏或功能障礙引起的。這是一種常見的遺傳性出血疾病。 VWF 的作用是與血管壁中的因子 VIII（一種關鍵的凝血蛋白）和血小板結合，並在凝血過程中幫助形成血小板栓。在馮維勒布蘭氏症中，凝血過程被延遲，導致受傷時失血過多。血管性血友病患者有多種治療方法，包括荷爾蒙療法和非荷爾蒙療法。

市場動態

由於馮·維勒布蘭德病在全球範圍內的高盛行率，該市場正在不斷成長。 2019年，預計殘疾人士將影響約1%的總人口；然而，具有臨床意義的疾病盛行率預計約為每百萬人 125 人，每百萬人中最多有 5 人患有嚴重疾病。根據世界血友病聯合會 2017 年進行的全球調查，全球有 76,144 人受到血管性血友病 (vWD) 的影響。對血管性血友病（VWD）的認知不斷提高以及患者援助計劃的增加也推動了市場的成長。馮維勒布蘭氏症 (VWD) 是一種罕見的遺傳性疾病，可能無法診斷，需要患者援助計劃提高意識。因此，許多組織和公司都致力於提高人們對血管性血友病的認知。例如，美國血液學會（ASH）採取了多項舉措，例如在拉丁美洲建立臨床研究培訓機構、實施全球研究獎和訪客培訓計劃，預計將在預測期內推動市場的成長。然而，高昂的治療費用對於血管性血友病（VWD）患者來說是一項重大挑戰。

研究報告涵蓋波特五力模型、市場吸引力分析和價值鏈分析。這些工具有助於清晰地了解行業結構並評估全球範圍內的競爭吸引力。此外，這些工具還對全球血管性血友病治療市場的每個細分市場進行了包容性評估。血管性血友病治療產業的成長和趨勢為本研究提供了整體方法。

市場區隔

馮維勒布蘭德疾病治療市場報告的這一部分提供了國家和區域層面細分市場的詳細資料，從而幫助策略師確定相應產品或服務的目標人口統計數據以及即將到來的機會。

依疾病類型

  • 1 型血管性血友病
  • 2 型血管性血友病
  • 3 型血管性血友病
  • 後天性血管性血友病

按藥物分類

  • 去氨加壓素
  • 凝血穩定藥物
  • 替代療法
  • 避孕藥具
  • 其他

依給藥途徑

  • 口服
  • 注射
  • 其他

按性別

  • 男士
  • 女性

按配銷通路

  • 醫院藥房
  • 零售藥局
  • 網路藥局

區域分析

本節涵蓋區域前景，重點介紹北美、歐洲、亞太地區、拉丁美洲以及中東和非洲的血管性血友病治療市場當前和未來的需求。此外，該報告重點關注所有主要地區各個應用領域的需求、估計和預測。

該研究報告還涵蓋了市場主要參與者的全面概況以及對全球競爭格局的深入了解。馮維勒布蘭德疾病治療市場的主要參與者包括 Octapharma AG、Grifols, SA.、Shire Plc、Bayer AG、CSL Behring、Pfizer Inc.、Ako Inc.、Ferring BV。本節包含競爭格局的整體視圖，包括各種策略發展，例如關鍵併購、未來產能、合作夥伴關係、財務概況、合作、新產品開發、新產品發布和其他發展。

如果您有任何客製化要求，請寫信給我們。我們的研究團隊可以根據您的需求提供客製化報告。

目錄

第1章：前言

  • 報告說明
    • 客觀的
    • 目標受眾
    • 獨特的銷售主張 (USP) 和產品
  • 研究範圍
  • 研究方法
    • 市場研究過程
    • 市場研究方法論

第 2 章：執行摘要

  • 市場亮點
  • 全球市場概況

第 3 章：血管性血友病治療 - 產業分析

  • 簡介 - 市場動態
  • 市場促進因素
  • 市場限制
  • 機會
  • 產業動態
  • 波特五力分析
  • 市場吸引力分析
    • 按疾病類型分類的市場吸引力分析
    • 藥品市場吸引力分析
    • 按給藥途徑進行的市場吸引力分析
    • 按性別分類的市場吸引力分析
    • 按配銷通路分類的市場吸引力分析
    • 市場吸引力分析：按地區

第 4 章：價值鏈分析

  • 價值鏈分析
  • 原料分析
    • 原料清單
    • 原料廠商清單
    • 主要原物料價格走勢
  • 潛在買家名單
  • 行銷管道
    • 直效行銷
    • 間接行銷
    • 行銷通路發展趨勢

第 5 章：全球血管性血友病治療市場分析：依疾病類型

  • 依疾病類型概述
  • 按疾病類型進行歷史和預測資料分析
  • 1 型血管性血友病
  • 2 型血管性血友病
  • 3 型血管性血友病
  • 後天性血管性血友病

第 6 章：全球血管性血友病治療市場分析：依藥物分類

  • 按藥物概述
  • 按藥物的歷史和預測數據分析
  • 去氨加壓素
  • 凝血穩定藥物
  • 替代療法
  • 避孕藥具
  • 其他

第 7 章：全球血管性血友病治療市場分析：依給藥途徑

  • 依給藥途徑概述
  • 按給藥途徑進行歷史和預測資料分析
  • 口服
  • 注射
  • 其他

第 8 章：全球血管性血友病治療市場分析：依性別

  • 按性別分類的概述
  • 按性別分類的歷史和預測資料分析
  • 男士
  • 女性

第 9 章：全球血管性血友病治療市場分析：按分銷管道

  • 配銷通路概覽
  • 按配銷通路進行歷史和預測資料分析
  • 醫院藥房
  • 零售藥局
  • 網路藥局

第 10 章：全球血管性血友病治療市場分析：依地理位置

  • 區域展望
  • 介紹
  • 北美銷售分析
    • 概覽、歷史與預測資料銷售分析
    • 北美按細分市場銷售分析
    • 北美按國家銷售分析
    • 美國銷售分析
    • 加拿大銷售分析
    • 墨西哥銷售分析
  • 歐洲銷售分析
    • 概覽、歷史與預測資料銷售分析
    • 歐洲按細分市場銷售分析
    • 歐洲按國家銷售分析
    • 英國銷售分析
    • 法國銷售分析
    • 德國銷售分析
    • 義大利銷售分析
    • 俄羅斯銷售分析
    • 歐洲其他地區銷售分析
  • 亞太地區銷售分析
    • 概覽、歷史與預測資料銷售分析
    • 亞太地區按細分市場銷售分析
    • 亞太地區按國家銷售分析
    • 中國銷售分析
    • 印度銷售分析
    • 日本銷售分析
    • 韓國銷售分析
    • 澳洲銷售分析
    • 東南亞銷售分析
    • 亞太地區其他地區銷售分析
  • 拉丁美洲銷售分析
    • 概覽、歷史與預測資料銷售分析
    • 拉丁美洲按細分市場銷售分析
    • 拉丁美洲按國家銷售分析
    • 巴西銷售分析
    • 阿根廷銷售分析
    • 秘魯銷售分析
    • 智利銷售分析
    • 拉丁美洲其他地區銷售分析
  • 中東和非洲銷售分析
    • 概覽、歷史與預測資料銷售分析
    • 中東和非洲按細分市場銷售分析
    • 中東和非洲按國家銷售分析
    • 沙烏地阿拉伯銷售分析
    • 阿拉伯聯合大公國銷售分析
    • 以色列銷售分析
    • 南非銷售分析
    • 中東其他地區和非洲銷售分析

第 11 章：血管性血友病治療公司的競爭格局

  • 馮維勒布蘭德疾病治療市場競爭
  • 夥伴關係/協作/協議
  • 併購
  • 新產品發布
  • 其他發展

第 12 章：公司簡介

  • 頂級公司市佔率分析
  • 市場集中度
  • Octapharma AG
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • Grifols SA.
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • Ferring BV
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • Shire Plc
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • Bayer AG
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • CSL Behring
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • Pfizer Inc.
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • Ako Inc.
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態

註 - 在公司概況中，財務詳細資訊和最新發展視情況而定，或對私人公司而言可能不包括在內

Product Code: VMR11215007

The global demand for Von Willebrand Disease Treatment Market is presumed to reach the market size of nearly USD 1065.41 Million by 2032 from USD 601.92 Million in 2023 with a CAGR of 6.55% under the study period 2024-2032.

Von Willebrand disease (VWD) is caused by a deficiency or dysfunctioning of a protein known as von Willebrand factor (VWF). It is a common genetic hemorrhagic disorder. The role of VWF is to binds with factor VIII(a key clotting protein) and platelets in blood vessel walls, and help form a platelet plug during the clotting process. In Von Willebrand disease the clotting process is delayed and leads to high blood loss in the incidence of injury. There are many treatments available for patients with von Willebrand disease including hormonal and non-hormonal therapies.

MARKET DYNAMICS

The market is growing due to the high prevalence of von Willebrand disease globally. In 2019, the PWD was projected to affect about 1% of the general population; however, clinically significant disease prevalence is predicted to be about 125 per million, with severe disease affecting up to 5 people per million. As per World Federation of Hemophilia's global survey conducted in the year 2017, 76,144 people were affected by von Willebrand disease (vWD) across the world. The rising awareness of von Willebrand disease (VWD) and increasing patient assistance programs are also driving the growth of the market. Von Willebrand disease (VWD) is a rare hereditary that may not be diagnosed and requires awareness in patient assistance programs. Therefore, many organizations and companies are focusing on increasing awareness among people about von Willebrand's disease. For example, the American Society of Hematology (ASH) takes several initiatives such as establishing the clinical research training institute in Latin America, implementing a global research award, and visitor training program, which is expected to boost the market's growth during the forecast period. However, the high cost of treatment is a significant challenge for patients with von Willebrand disease (VWD).

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Von Willebrand Disease Treatment. The growth and trends of Von Willebrand Disease Treatment industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Von Willebrand Disease Treatment market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Disease Type

  • Type 1 Von Willebrand Disease
  • Type 2 Von Willebrand Disease
  • Type 3 Von Willebrand Disease
  • Acquired Von Willebrand Disease

By Drug

  • Desmopressin
  • Clotstabilizing Medications
  • Replacement Therapies
  • Contraceptives
  • Others

By Route of Administration

  • Oral
  • Injection
  • Others

By Gender

  • Men
  • Women

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Von Willebrand Disease Treatment market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Von Willebrand Disease Treatment market include Octapharma AG, Grifols, SA., Shire Plc, Bayer AG, CSL Behring, Pfizer Inc., Ako Inc., Ferring BV. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Report Description
    • 1.1.1 Objective
    • 1.1.2 Target Audience
    • 1.1.3 Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1 Market Research Process
    • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3. VON WILLEBRAND DISEASE TREATMENT - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Disease Type
    • 3.7.2 Market Attractiveness Analysis By Drug
    • 3.7.3 Market Attractiveness Analysis By Route of Administration
    • 3.7.4 Market Attractiveness Analysis By Gender
    • 3.7.5 Market Attractiveness Analysis By Distribution Channel
    • 3.7.6 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1 List of Raw Materials
    • 4.2.2 Raw Material Manufactures List
    • 4.2.3 Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1 Direct Marketing
    • 4.4.2 Indirect Marketing
    • 4.4.3 Marketing Channel Development Trend

5. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET ANALYSIS BY DISEASE TYPE

  • 5.1. Overview By Disease Type
  • 5.2. Historical and Forecast Data Analysis By Disease Type
  • 5.3. Type 1 Von Willebrand Disease Historic and Forecast Sales By Regions
  • 5.4. Type 2 Von Willebrand Disease Historic and Forecast Sales By Regions
  • 5.5. Type 3 Von Willebrand Disease Historic and Forecast Sales By Regions
  • 5.6. Acquired Von Willebrand Disease Historic and Forecast Sales By Regions

6. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET ANALYSIS BY DRUG

  • 6.1. Overview By Drug
  • 6.2. Historical and Forecast Data Analysis By Drug
  • 6.3. Desmopressin Historic and Forecast Sales By Regions
  • 6.4. Clotstabilizing Medications Historic and Forecast Sales By Regions
  • 6.5. Replacement Therapies Historic and Forecast Sales By Regions
  • 6.6. Contraceptives Historic and Forecast Sales By Regions
  • 6.7. Others Historic and Forecast Sales By Regions

7. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

  • 7.1. Overview By Route of Administration
  • 7.2. Historical and Forecast Data Analysis By Route of Administration
  • 7.3. Oral Historic and Forecast Sales By Regions
  • 7.4. Injection Historic and Forecast Sales By Regions
  • 7.5. Others Historic and Forecast Sales By Regions

8. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET ANALYSIS BY GENDER

  • 8.1. Overview By Gender
  • 8.2. Historical and Forecast Data Analysis By Gender
  • 8.3. Men Historic and Forecast Sales By Regions
  • 8.4. Women Historic and Forecast Sales By Regions

9. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET ANALYSIS BY DISTRIBUTION CHANNEL

  • 9.1. Overview By Distribution Channel
  • 9.2. Historical and Forecast Data Analysis By Distribution Channel
  • 9.3. Hospital Pharmacies Historic and Forecast Sales By Regions
  • 9.4. Retail Pharmacies Historic and Forecast Sales By Regions
  • 9.5. Online Pharmacies Historic and Forecast Sales By Regions

10. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET ANALYSIS BY GEOGRAPHY

  • 10.1. Regional Outlook
  • 10.2. Introduction
  • 10.3. North America Sales Analysis
    • 10.3.1 Overview, Historic and Forecast Data Sales Analysis
    • 10.3.2 North America By Segment Sales Analysis
    • 10.3.3 North America By Country Sales Analysis
    • 10.3.4 United States Sales Analysis
    • 10.3.5 Canada Sales Analysis
    • 10.3.6 Mexico Sales Analysis
  • 10.4. Europe Sales Analysis
    • 10.4.1 Overview, Historic and Forecast Data Sales Analysis
    • 10.4.2 Europe By Segment Sales Analysis
    • 10.4.3 Europe By Country Sales Analysis
    • 10.4.4 United Kingdom Sales Analysis
    • 10.4.5 France Sales Analysis
    • 10.4.6 Germany Sales Analysis
    • 10.4.7 Italy Sales Analysis
    • 10.4.8 Russia Sales Analysis
    • 10.4.9 Rest Of Europe Sales Analysis
  • 10.5. Asia Pacific Sales Analysis
    • 10.5.1 Overview, Historic and Forecast Data Sales Analysis
    • 10.5.2 Asia Pacific By Segment Sales Analysis
    • 10.5.3 Asia Pacific By Country Sales Analysis
    • 10.5.4 China Sales Analysis
    • 10.5.5 India Sales Analysis
    • 10.5.6 Japan Sales Analysis
    • 10.5.7 South Korea Sales Analysis
    • 10.5.8 Australia Sales Analysis
    • 10.5.9 South East Asia Sales Analysis
    • 10.5.10 Rest Of Asia Pacific Sales Analysis
  • 10.6. Latin America Sales Analysis
    • 10.6.1 Overview, Historic and Forecast Data Sales Analysis
    • 10.6.2 Latin America By Segment Sales Analysis
    • 10.6.3 Latin America By Country Sales Analysis
    • 10.6.4 Brazil Sales Analysis
    • 10.6.5 Argentina Sales Analysis
    • 10.6.6 Peru Sales Analysis
    • 10.6.7 Chile Sales Analysis
    • 10.6.8 Rest of Latin America Sales Analysis
  • 10.7. Middle East & Africa Sales Analysis
    • 10.7.1 Overview, Historic and Forecast Data Sales Analysis
    • 10.7.2 Middle East & Africa By Segment Sales Analysis
    • 10.7.3 Middle East & Africa By Country Sales Analysis
    • 10.7.4 Saudi Arabia Sales Analysis
    • 10.7.5 UAE Sales Analysis
    • 10.7.6 Israel Sales Analysis
    • 10.7.7 South Africa Sales Analysis
    • 10.7.8 Rest Of Middle East And Africa Sales Analysis

11. COMPETITIVE LANDSCAPE OF THE VON WILLEBRAND DISEASE TREATMENT COMPANIES

  • 11.1. Von Willebrand Disease Treatment Market Competition
  • 11.2. Partnership/Collaboration/Agreement
  • 11.3. Merger And Acquisitions
  • 11.4. New Product Launch
  • 11.5. Other Developments

12. COMPANY PROFILES OF VON WILLEBRAND DISEASE TREATMENT INDUSTRY

  • 12.1. Top Companies Market Share Analysis
  • 12.2. Market Concentration Rate
  • 12.3. Octapharma AG
    • 12.3.1 Company Overview
    • 12.3.2 Company Revenue
    • 12.3.3 Products
    • 12.3.4 Recent Developments
  • 12.4. Grifols SA.
    • 12.4.1 Company Overview
    • 12.4.2 Company Revenue
    • 12.4.3 Products
    • 12.4.4 Recent Developments
  • 12.5. Ferring BV
    • 12.5.1 Company Overview
    • 12.5.2 Company Revenue
    • 12.5.3 Products
    • 12.5.4 Recent Developments
  • 12.6. Shire Plc
    • 12.6.1 Company Overview
    • 12.6.2 Company Revenue
    • 12.6.3 Products
    • 12.6.4 Recent Developments
  • 12.7. Bayer AG
    • 12.7.1 Company Overview
    • 12.7.2 Company Revenue
    • 12.7.3 Products
    • 12.7.4 Recent Developments
  • 12.8. CSL Behring
    • 12.8.1 Company Overview
    • 12.8.2 Company Revenue
    • 12.8.3 Products
    • 12.8.4 Recent Developments
  • 12.9. Pfizer Inc.
    • 12.9.1 Company Overview
    • 12.9.2 Company Revenue
    • 12.9.3 Products
    • 12.9.4 Recent Developments
  • 12.10. Ako Inc.
    • 12.10.1 Company Overview
    • 12.10.2 Company Revenue
    • 12.10.3 Products
    • 12.10.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies

LIST OF TABLES

  • Market Snapshot
  • Drivers: Impact Analysis
  • Restraints: Impact Analysis
  • List of Raw Material
  • List of Raw Material Manufactures
  • Analysis By Disease Type (USD MN)
  • Type 1 Von Willebrand Disease Market Sales By Geography (USD MN)
  • Type 2 Von Willebrand Disease Market Sales By Geography (USD MN)
  • Type 3 Von Willebrand Disease Market Sales By Geography (USD MN)
  • Acquired Von Willebrand Disease Market Sales By Geography (USD MN)
  • Analysis By Drug (USD MN)
  • Desmopressin Market Sales By Geography (USD MN)
  • Clotstabilizing Medications Market Sales By Geography (USD MN)
  • Replacement Therapies Market Sales By Geography (USD MN)
  • Contraceptives Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Analysis By Route of Administration (USD MN)
  • Oral Market Sales By Geography (USD MN)
  • Injection Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Analysis By Gender (USD MN)
  • Men Market Sales By Geography (USD MN)
  • Women Market Sales By Geography (USD MN)
  • Analysis By Distribution Channel (USD MN)
  • Hospital Pharmacies Market Sales By Geography (USD MN)
  • Retail Pharmacies Market Sales By Geography (USD MN)
  • Online Pharmacies Market Sales By Geography (USD MN)
  • Global Von Willebrand Disease Treatment Market Sales By Geography (USD MN)
  • North America Market Analysis (USD MN)
  • United States Market Analysis (USD MN)
  • Canada Market Analysis (USD MN)
  • Mexico Market Analysis (USD MN)
  • Europe Market Analysis (USD MN)
  • Europe Market Estimate By Country (USD MN)
  • United Kingdom Market Analysis (USD MN)
  • France Market Analysis (USD MN)
  • Germany Market Analysis (USD MN)
  • Italy Market Analysis (USD MN)
  • Russia Market Analysis (USD MN)
  • Spain Market Analysis (USD MN)
  • Rest of Europe Market Analysis (USD MN)
  • Asia Pacific Market Analysis (USD MN)
  • China Market Analysis (USD MN)
  • Japan Market Analysis (USD MN)
  • India Market Analysis (USD MN)
  • South Korea Market Analysis (USD MN)
  • Australia Market Analysis (USD MN)
  • South East Asia Market Analysis (USD MN)
  • Rest of Asia Pacific Market Analysis (USD MN)
  • Latin America Market Analysis (USD MN)
  • Brazil Market Analysis (USD MN)
  • Argentina Market Analysis (USD MN)
  • Peru Market Analysis (USD MN)
  • Chile Market Analysis (USD MN)
  • Rest of Latin America Market Analysis (USD MN)
  • Middle East & Africa Market Analysis (USD MN)
  • Saudi Arabia Market Analysis (USD MN)
  • UAE Market Analysis (USD MN)
  • Israel Market Analysis (USD MN)
  • South Africa Market Analysis (USD MN)
  • Rest of Middle East and Africa Market Analysis (USD MN)
  • Partnership/Collaboration/Agreement
  • Mergers And Acquisition

LIST OF FIGURES

  • Research Scope of Von Willebrand Disease Treatment Report
  • Market Research Process
  • Market Research Methodology
  • Global Von Willebrand Disease Treatment Market Size, By Region (USD MN)
  • Porters Five Forces Analysis
  • Market Attractiveness Analysis By Disease Type
  • Market Attractiveness Analysis By Drug
  • Market Attractiveness Analysis By Route of Administration
  • Market Attractiveness Analysis By Gender
  • Market Attractiveness Analysis By Distribution Channel
  • Market Attractiveness Analysis By Region
  • Value Chain Analysis
  • Global Market Analysis By Disease Type (USD MN)
  • Type 1 Von Willebrand Disease Market Sales By Geography (USD MN)
  • Type 2 Von Willebrand Disease Market Sales By Geography (USD MN)
  • Type 3 Von Willebrand Disease Market Sales By Geography (USD MN)
  • Acquired Von Willebrand Disease Market Sales By Geography (USD MN)
  • Global Market Analysis By Drug (USD MN)
  • Desmopressin Market Sales By Geography (USD MN)
  • Clotstabilizing Medications Market Sales By Geography (USD MN)
  • Replacement Therapies Market Sales By Geography (USD MN)
  • Contraceptives Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Global Market Analysis By Route of Administration (USD MN)
  • Oral Market Sales By Geography (USD MN)
  • Injection Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Global Market Analysis By Gender (USD MN)
  • Men Market Sales By Geography (USD MN)
  • Women Market Sales By Geography (USD MN)
  • Global Market Analysis By Distribution Channel (USD MN)
  • Hospital Pharmacies Market Sales By Geography (USD MN)
  • Retail Pharmacies Market Sales By Geography (USD MN)
  • Online Pharmacies Market Sales By Geography (USD MN)
  • Global Market Sales (USD MN)
  • North America Market Sales (USD MN)
  • Europe Market Sales (USD MN)
  • Asia Pacific Market Sales (USD MN)
  • Latin America Market Sales (USD MN)
  • Middle East & Africa Market Sales (USD MN)
  • Recent Development in Industry
  • Top Company Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.